Trimada in the Management of Medoroga

A Pharmaco-clinical Study of Trimada in the Management of Medoroga w.s.r. to Dyslipidemia - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054809

Enrollment

Registered

2023-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who will give written consent for the study. 2.Patients fulfiling the diagnostic criteria as per clinical performa. 3.Any one of the following: a)Dyslipidemia in laboratory investigation. b)Patients having raised BMI between 25-39.9kg/metre square

Exclusion criteria

Exclusion criteria: 1. Persons who will not agree to give written consent for the study 2. Patients below the age of 18 years and 60 years above 3. Pregnancy and lactating mothers 4.Patients having history of severe cardiac diseases

Design outcomes

Primary

Measure	Time frame
Subjective Parameter- Grading will be done with signs & symptoms of Dyslipidemia/Medoroga. Lipid profile, CBC, LFT, KFTTimepoint: After 45 days of intervention of Trimada Churan orally & 15 days after stopping of medicine.	—

Secondary

Measure	Time frame
Subjective Parameter- Grading will be done with signs & symptoms of Dyslipidemia/Medoroga. Lipid profile, CBC, LFT, KFTTimepoint: After 45 days of intervention of Trimada Churan orally & 15 days after stopping of medicine.	—

Countries

India

Contacts

Public ContactDr Rosy Gupta

Post graduate training and research institute Government Ayurvedic College, Patiala, Punjab

rrgu04@gmail.com9815818190

Outcome results